Tariqul Haque Tuhin

Tariqul Haque Tuhin

Auto-generated profile, based on publicly available information

Tariqul Haque Tuhin

Pharmacokinetics and Drug Metabolism, Amgen Research, 750 Gateway Blvd, Suite 100, South San Francisco, California 94080, United States

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TAToufiq Ul Amin
Toufiq Ul Amin
RERasha Emara
Rasha Emara
APArindom Pal
Arindom Pal
HAHala Aldawod
Hala Aldawod
GJGuanming Jiang
Guanming Jiang
MAMamoun M. Alhamadsheh
Mamoun M. Alhamadsheh

19 June 2024 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
MBMark A. Bryniarski
Mark A. Bryniarski
TTTariqul Haque Tuhin
Tariqul Haque Tuhin
TATimothy M. Acker
Timothy M. Acker
DWDevin Wakefield
Devin Wakefield
PSPanijaya (Gemy) Sethaputra
Panijaya (Gemy) Sethaputra
KCKip P. Conner
Kip P. Conner
In vivo clearance mechanisms of therapeutic monoclonal antibodies (mAbs) encompass both target-mediated and target-independent processes. Two distinct determinants of overall mAb clearance largely separate of target-mediated influences are non-specific cellular endocytosis and subsequent pH-dependent mAb recycling mediated by the neonatal Fc receptor (FcRn), where inter-mAb variability in the efficiency of both processes is observed. Here, we implemented a functional cell-based FcRn recycling assay via Madin-Darby canine kidney type II cells stably co-transfected with human FcRn and its light chain β2-microglobulin. A series of pH-dependent internalization studies using a model antibody demonstrated proper function of the human FcRn complex. We then applied our cellular assays to assess the contribution of FcRn and non-specific interactions in the cellular turnover for a panel of 8 clinically relevant mAbs exhibiting variable human pharmacokinetic behavior. Our results demonstrate that non-specific endocytosis rates, pH-dependent non-specific interactions, and engagement with FcRn all contribute to the overall recycling efficiency of therapeutic monoclonal antibodies. The predictive capacity of our assay approach was highlighted by successful identification of all mAbs within our panel possessing clearance in humans greater than 5 mL/day/kg. These results demonstrate that a combination of cell-based in vitro assays can properly resolve individual mechanisms underlying the overall in vivo recycling efficiency and non-target mediated clearance of therapeutic mAbs.

16 January 2026 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
MBMark A. Bryniarski
Mark A. Bryniarski
SWSongyu Wang
Songyu Wang
ACAochiu Chen
Aochiu Chen
BCBrian Coventry
Brian Coventry
EKElif Nihal Korkmaz
Elif Nihal Korkmaz
KCKevin D. Cook
Kevin D. Cook